BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69:785-792. [PMID: 30227916 DOI: 10.1016/j.jhep.2018.05.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Corma-gómez A, Pineda JA. Hepatitis C virus infection in Spain: Challenges in the track to elimination. Enfermedades Infecciosas y Microbiología Clínica 2019;37:219-21. [DOI: 10.1016/j.eimc.2019.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 García F, Domínguez-Hernández R, Casado M, Macías J, Téllez F, Pascasio JM, Casado MÁ, Alados JC. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:634-41. [PMID: 30982677 DOI: 10.1016/j.eimc.2019.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
3 Ledesma F, Buti M, Domínguez-Hernández R, Casado MA, Esteban R. Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence. Rev Esp Quimioter 2020;33:240-8. [PMID: 32510188 DOI: 10.37201/req/030.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M, Zhuo Y, Fagiuoli S, Petersen J, Chhatwal J. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9:e026726. [PMID: 31189677 DOI: 10.1136/bmjopen-2018-026726] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
5 Velosa J, Macedo G. Elimination of Hepatitis C in Portugal: An Urban Legend? GE Port J Gastroenterol 2020;27:166-71. [PMID: 32509922 DOI: 10.1159/000505582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Choi GH, Jang ES, Kim JW, Jeong SH. A Survey of the Knowledge of and Testing Rate for Hepatitis C in the General Population in South Korea. Gut Liver 2020;14:808-16. [PMID: 32066209 DOI: 10.5009/gnl19296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Iliaz R, Yuce T, Torun S, Cavus B, Gulluoglu M, Bozaci M, Karaca C, Akyuz F, Demir K, Besisik F, Kaymakoglu S. Changing epidemiology of chronic hepatitis C: patients are older and at a more advanced stage at the time of diagnosis. Eur J Gastroenterol Hepatol 2019;31:1247-9. [PMID: 30913053 DOI: 10.1097/MEG.0000000000001406] [Reference Citation Analysis]
8 Popping S, Bade D, Boucher C, van der Valk M, El-sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-burban S, Ninburg M, Feld J, Hellard M, Ward J. The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. Journal of Virus Eradication 2019;5:60-6. [DOI: 10.1016/s2055-6640(20)30281-8] [Cited by in Crossref: 29] [Article Influence: 9.7] [Reference Citation Analysis]
9 Tran A, Shili-Masmoudi S, Moga L, Chevaliez S, Luciani A, Ruiz I, Ganne-Carrié N, Bureau C, Bourlière M, de Lédinghen V. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF CHRONIC INFECTION WITH HEPATITIS C VIRUS. Clin Res Hepatol Gastroenterol 2021;:101771. [PMID: 34332129 DOI: 10.1016/j.clinre.2021.101771] [Reference Citation Analysis]
10 Houri I, Horowitz N, Katchman H, Weksler Y, Miller O, Deutsch L, Shibolet O. Emergency department targeted screening for hepatitis C does not improve linkage to care. World J Gastroenterol 2020; 26(32): 4878-4888 [PMID: 32921964 DOI: 10.3748/wjg.v26.i32.4878] [Reference Citation Analysis]
11 Wang JH, Chen CH, Chang CM, Feng WC, Lee CY, Lu SN. Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan. J Formos Med Assoc 2020;119:504-8. [PMID: 31350109 DOI: 10.1016/j.jfma.2019.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
12 Brunner N, Bruggmann P. Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. J Prev Med Public Health 2021;54:251-8. [PMID: 34370938 DOI: 10.3961/jpmph.21.151] [Reference Citation Analysis]
13 Carty PG, Fawsitt CG, Gillespie P, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations. Appl Health Econ Health Policy 2021. [PMID: 34870793 DOI: 10.1007/s40258-021-00694-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Brouard C, Saboni L, Gautier A, Chevaliez S, Rahib D, Richard JB, Barin F, Larsen C, Sommen C, Pillonel J, Delarocque-Astagneau E, Lydié N, Lot F; 2016 Health Barometer Group. HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy. BMC Infect Dis 2019;19:896. [PMID: 31660879 DOI: 10.1186/s12879-019-4493-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
15 Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, Negro F. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030? PLoS One 2018;13:e0209374. [PMID: 30596701 DOI: 10.1371/journal.pone.0209374] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, Chhatwal J, Esmat G, Hutchinson S, Malliori MM, Maticic M, Mozalevskis A, Negro F, Papandreou GA, Papatheodoridis GV, Peck-Radosavljevic M, Razavi H, Reic T, Schatz E, Tozun N, Younossi Z, Manns MP. Securing sustainable funding for viral hepatitis elimination plans. Liver Int. 2020;40:260-270. [PMID: 31808281 DOI: 10.1111/liv.14282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
17 Mason LMK, Veldhuijzen IK, Duffell E, van Ahee A, Bunge EM, Amato-Gauci AJ, Tavoschi L. Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review. J Viral Hepat 2019;26:1431-53. [PMID: 31332919 DOI: 10.1111/jvh.13182] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
18 Tatemichi M, Furuya H, Nagahama S, Takaya N, Shida Y, Fukai K, Owada S, Endo H, Kinoue T, Korenaga M. A nationwide cross-sectional survey on hepatitis B and C screening among workers in Japan. Sci Rep 2020;10:11435. [PMID: 32651421 DOI: 10.1038/s41598-020-68021-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
19 Brouard C, Pillonel J, Boussac M, de Lédinghen V, Rachas A, Silvain C, Lydié N, Chevaliez S, Pioche C, Durand J, Lot F, Delarocque-Astagneau E. French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long. BMC Infect Dis 2020;20:759. [PMID: 33059617 DOI: 10.1186/s12879-020-05478-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Kileng H, Gutteberg T, Goll R, Paulssen EJ. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. BMC Infect Dis 2019;19:189. [PMID: 30808290 DOI: 10.1186/s12879-019-3832-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Elwood C, Sauve LJ, Pick N. Preventing vertical transmission of HCV in Canada. CMAJ 2019;191:E650-1. [PMID: 31209131 DOI: 10.1503/cmaj.181662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Sadeghimehr M, Bertisch B, Negro F, Butsashvili M, Shilton S, Tskhomelidze I, Tsereteli M, Keiser O, Estill J. Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis. PeerJ 2021;9:e11895. [PMID: 34595063 DOI: 10.7717/peerj.11895] [Reference Citation Analysis]
23 Kondili LA, Gamkrelidze I, Blach S, Marcellusi A, Galli M, Petta S, Puoti M, Vella S, Razavi H, Craxi A, Mennini FS; PITER collaborating group. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver Int 2020;40:1545-55. [PMID: 32078234 DOI: 10.1111/liv.14408] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
24 Pawlotsky J, Ramers CB, Dillon JF, Feld JJ, Lazarus JV. Simplification of Care for Chronic Hepatitis C Virus Infection. Semin Liver Dis 2020;40:392-402. [DOI: 10.1055/s-0040-1713657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
25 Lombardi A, Mondelli MU; ESCMID Study Group for Viral Hepatitis (ESGVH). Hepatitis C: Is eradication possible? Liver Int 2019;39:416-26. [DOI: 10.1111/liv.14011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
26 Brunner P, Brunner K, Kübler D. The Cost-Effectiveness of HIV/STI Prevention in High-Income Countries with Concentrated Epidemic Settings: A Scoping Review. AIDS Behav 2022. [PMID: 35034238 DOI: 10.1007/s10461-022-03583-y] [Reference Citation Analysis]
27 Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018;25 Suppl 3:6-14. [PMID: 30398294 DOI: 10.1111/jvh.13005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
28 Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma 2019;6:131-41. [PMID: 31440486 DOI: 10.2147/JHC.S159269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
29 Kåberg M, Weiland O. Hepatitis C elimination - Macro-elimination. Liver Int 2020;40 Suppl 1:61-6. [PMID: 32077600 DOI: 10.1111/liv.14352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Duchesne L, Hejblum G, Njouom R, Touré Kane C, Toni TD, Moh R, Sylla B, Rouveau N, Attia A, Lacombe K. Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa. PLoS One 2020;15:e0238035. [PMID: 32833976 DOI: 10.1371/journal.pone.0238035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
31 Williams J, Miners A, Harris R, Mandal S, Simmons R, Ireland G, Hickman M, Gore C, Vickerman P. Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England. Value in Health 2019;22:1248-56. [DOI: 10.1016/j.jval.2019.06.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
32 Cenderello G, Taramasso L, Marra D, Orcamo P, Pasa A, Di Biagio A. HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation. Expert Rev Pharmacoecon Outcomes Res. 2019;19:189-193. [PMID: 30321071 DOI: 10.1080/14737167.2019.1537124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
33 Botterman R, Verhelst X, Buffel V, Derese A, Van Der Paelt T, De Volder G, Van Vlierberghe H, Boeckxstaens P. Hepatitis C in two general practices in Flanders, Belgium: is there a need to reconsider current screening recommendations? Acta Clin Belg 2020;:1-8. [PMID: 32436785 DOI: 10.1080/17843286.2020.1763670] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Kim DY, Wong G, Lee J, Kim MH, Smith N, Blissett R, Kim HJ. Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea. Curr Med Res Opin 2020;36:993-1002. [PMID: 32295431 DOI: 10.1080/03007995.2020.1756232] [Reference Citation Analysis]